PVLA — Palvella Therapeutics Share News
0.000.00%
Last trade - 00:00Brief: Palvella Therapeutics To Expand Phase 3 Selva Clinical Trial Of Qtorin™ 3.9% Rapamycin Anhydrous Gel (Qtorin™ Rapamycin)
Brief: Palvella Therapeutics Publishes Results From Phase 2 Clinical Trial Of Qtorin In The Journal Of Vascular Anomalies
Brief: Palvella Therapeutics Doses First Patients In Phase 2 Toiva Clinical Trial Of Qtorin
U.S. RESEARCH ROUNDUP-Apple, EverQuote, UnitedHealth
H.C. Wainwright starts coverage of Palvella Therapeutics with 'buy' rating
Brief: Palvella Therapeutics Appoints Matthew Korenberg As Chief Financial Officer
Brief: Palvella Therapeutics And Pieris Pharmaceuticals Announce Definitive Merger Agreement
Brief: Pieris Pharmaceuticals Announces 1-For-80 Reverse Stock Split
Brief: Pieris To Cut Workforce In Second Quarter
Pieris Pharmaceuticals Inc expected to post a loss of 11 cents a share - Earnings Preview
Brief: Pieris Pharmaceuticals Says On August 30 Board Approved Retention Benefits For Retained Employees In Connection With Workplace Restructuring
Pieris Pharmaceuticals Inc expected to post a loss of 16 cents a share - Earnings Preview
Pieris Pharma jumps on job cut, strategic option plans
Brief: Pieris Pharmaceuticals Initiated A Corporate Restructuring
Pieris Pharma slumps as partner AstraZeneca to stop asthma drug study
U.S. STOCKS ON THE MOVE-PureCycle, Amazon.com, Dollar Tree
U.S. STOCKS ON THE MOVE-PureCycle, Walt Disney, Chipotle Mexican Grill
U.S. STOCKS ON THE MOVE-Harley-Davidson, Eightco, Beauty Health
Pieris Pharma slumps as partner AstraZeneca to stop asthma drug study